Amarin Reports Overall Survival Improvement in Liver Metastasis Trial

Amarin said the University of Leeds-sponsored Phase 3 EMT2 trial did not meet its primary progression-free survival endpoint, while its key secondary overall survival endpoint improved. The trial evaluated icosapent ethyl alongside standard care in patients undergoing liver resection for colorectal cancer liver metastases.